natgillin/translations-raw huggingface dataset:
Zinbryta is a colourless to slightly yellow, clear to opalescent liquid contained within a syringe/pen.
Zdravilo Zinbryta je brezbarvna do rumenkasta, bistra do opalescentna tekočina v injekcijski brizgi/injekcijskem peresniku.
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS) (see section 5.1).
Zdravilo Zinbryta je indicirano za zdravljenje odraslih bolnikov z recidivno obliko multiple skleroze (glejte poglavje 5.1).
Zinbryta is not appropriate for use in patients with pre-existing severe hepatic impairment (Child-Pugh class C) (see section 4.4).
Zdravilo Zinbryta se ne uporablja pri bolnikih z obstoječo hudo okvaro jeter (razred C po Child-Pughu) (glejte poglavje 4.4).
Zinbryta is not expected to undergo metabolism by hepatic enzymes or renal elimination.
Ne pričakuje se, da bi se zdravilo Zinbryta presnavljalo z jetrnimi encimi ali z ledvičnim izločanjem.
Zinbryta is used to treat relapsing forms of multiple sclerosis (MS) in adults.
Zdravilo Zinbryta se uporablja za zdravljenje recidivne oblike multiple skleroze (MS) pri odraslih.
Zinbryta may cause serious liver problems so your doctor will decide if Zinbryta is suitable for you.
Zdravilo Zinbryta lahko povzroči resne težave z jetri, zato se bo zdravnik odločil, ali je zdravilo Zinbryta za vas primerno.
Zinbryta may cause serious liver problems.
Zdravilo Zinbryta lahko povzroči resne težave z jetri.
Zinbryta pre-filled syringe
Zdravilo Zinbryta napolnjena injekcijska brizga
Zinbryta pre-filled syringe is for injecting the medicine under the skin only (subcutaneous).
Zdravilo Zinbryta napolnjena injekcijska brizga je samo za injiciranje zdravila pod kožo (subkutano).
Zinbryta will be prescribed to you by a doctor experienced in the treatment of MS.
Zdravilo Zinbryta vam bo predpisal zdravnik z izkušnjami z zdravljenjem MS.
Zinbryta works by stopping the body’s immune system from damaging your brain and spinal cord.
Zdravilo Zinbryta učinkuje tako, da telesnemu imunskemu sistemu preprečuje poškodovanje možganov in hrbtenjače.
Zinc chloride Metacresol Glycerol
Cinkov klorid M-krezol Glicerol
zinc chloride, glycerol, metacresol, disodium phosphate dihydrate, sodium hydroxide, hydrochloric acid and water for injections.
cinkov klorid, glicerol, metakrezol, natrijev hidrogenfosfat dihidrat, natrijev hidroksid, klorovodikova kislina in voda za injekcije
zinc chloride, glycerol, metacresol, phenol, disodium phosphate dihydrate, sodium hydroxide/hydrochloric acid for pH adjustment, protamine sulfate and water for injections
cinkov klorid, glicerol, metakrezol, fenol, natrijev hidrogenfosfat dihidrat, natrijev hidroksid/klorovodikovo kislino za uravnavanje pH, protaminijev sulfat in vodo za injekcije.
zinc chloride, glycerol, metacresol, sodium hydroxide/hydrochloric acid for pH adjustment and water for injections
cinkov klorid, glicerol, metakrezol, natrijev hidroksid/klorovodikovo kislino za uravnavanje pH in vodo za injekcije.
Zinc chloride, metacresol, glycerol, hydrochloric acid / sodium hydroxide (for pH adjustment), water for injections
Cinkov klorid, metakrezol, glicerol, klorovodikova kislina /, natrijev hidroksid (za prilagoditev pH), voda za injekcije.
zinc chloride, trometamol, poloxamer 171, glycerol, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injections
cinkov klorid, trometamol, poloksamer 171, glicerol, klorovodikova kislina (za prilagoditev pH), natrijev hidroksid (za prilagoditev pH), voda za injekcije.
zinc chloride, trometamol, poloxamer 171, glycerol, hydrochloric acid (for pH adjustment), water for injections.
cinkov klorid, trometamol, poloksamer 171, glicerol, klorovodikova kislina (za uravnavanje pH), voda za injekcije.
Zinc has been used to treat Wilson’s disease since 1958.
Cink se za zdravljenje Wilsonove bolezni uporablja od leta 1958 naprej.
Zinforo ceftaroline fosamil
Zinforo fosamilceftarolin
Zinforo dose adjustment is not required in elderly patients with creatinine clearance above 50 ml/min.
Starejšim bolnikom z očistkom kreatinina nad 50 ml/min odmerka zdravila Zinforo ni treba prilagoditi.
Zinforo is a pale yellowish-white to light yellow powder for concentrate for solution for infusion in a vial.
Zdravilo Zinforo je bledo rumenkastobel do svetlo rumen prašek za koncentrat za raztopino za infundiranje v viali.
Zinforo is a powder that is made up into a solution for infusion (drip) into a vein.
Zdravilo Zinforo je prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
Zinforo is administered by intravenous infusion over 60 minutes for all infusion volumes (50 ml, 100 ml or 250 ml) (see section 6.6).
Zdravilo Zinforo se daje v intravenski infuziji 60 minut in velja za vse infuzijske volumne (50 ml, 100 ml ali 250 ml) (glejte poglavje 6.6).
Zinforo is contraindicated in patients with a history of hypersensitivity to cephalosporins.
Zdravilo Zinforo je kontraindicirano pri bolnikih z anamnezo preobčutljivosti za cefalosporine.
Zinforo is indicated for the treatment of the following infections in adults and children from the age of 2 months (see sections 4.4 and 5.1):
Zdravilo Zinforo je indicirano pri odraslih in otrocih od 2. meseca starosti naprej za zdravljenje naslednjih okužb (glejte poglavji 4.4 in 5.1):
Zinforo is used to treat children from the age of 2 months and adults with:
Zdravilo Zinforo se uporablja za zdravljenje otrok od 2. meseca starosti in odraslih z:
Zinforo may cause side effects such as dizziness.
Zdravilo Zinforo lahko povzroči neželene učinke, npr. omotico.
Zinforo must also not be used in patients who are hypersensitive to other antibiotics belonging to the cephalosporin class and those who are severely allergic to other beta- lactam antibiotics.
Prav tako ga ne smejo uporabljati bolniki, ki so preobčutljivi za druge antibiotike iz skupine cefalosporinov, in tisti, ki so hudo alergični na druge betalaktamske antibiotike.
Zinforo powder should be reconstituted with 20 ml of sterile water for injections.
Prašek Zinforo je treba pripraviti z 20 ml sterilne vode za injekcije.
Zinforo should be used with caution in patients with a history of any other type of hypersensitivity reaction to penicillins or carbapenems.
Pri bolnikih z anamnezo preobčutljivosti za peniciline ali karbapeneme je potrebna previdnost pri jemanju zdravila Zinforo.
Zinforo should not be used in children below the age of 2 months as not enough data exist in these populations.
Ker ni na voljo dovolj podatkov pri teh skupinah bolnikov, se zdravila Zinforo ne sme uporabljati pri otrocih mlajših od 2 mesecev.
Zinforo was as effective as the other antibiotics in treating both skin and soft tissue infections and pneumonia in adults:
Zdravilo Zinforo je bilo pri zdravljenju obeh vrst okužb enako učinkovito kot drugi antibiotiki:
Zinforo works by killing certain bacteria, which can cause serious infections.
Zdravilo Zinforo deluje tako, da uničuje določene bakterije, ki lahko povzročijo hude okužbe.
ZIPPED SEALABLE BAG
VREČA, KI SE ZAPIRA Z ZADRGO
Ziprasidone
ziprazidon
Zoely has no or negligible effect on your ability to drive and use machines.
Zdravilo Zoely nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Zoely is a medicine available as 24 white ‘active’ tablets that contain the active substances nomegestrol acetate (2.5 mg) and estradiol (1.5 mg), and four yellow ‘inactive’ (placebo) tablets that do not contain any active substance.
Zdravilo Zoely je na voljo v obliki 24 belih „aktivnih“ tablet, ki vsebujejo zdravilni učinkovini nomegestrolacetat (2,5 mg) in estradiol (1,5 mg), in štirih rumenih „neaktivnih“ (placebo) tablet, ki ne vsebujejo zdravilnih učinkovin.
Zoely is not indicated during pregnancy.
Zdravilo Zoely ni indicirano za uporabo med nosečnostjo.
Zoely may also interfere with the working of other medicines – such as the anti-epileptic lamotrigine.
Tudi zdravilo Zoely lahko moti delovanje drugih zdravil, npr. antiepileptika lamotrigina.
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve Belgija
Zoetis Belgium SA Rue Laid Burniat, 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA, Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIUM
Zoetis Belgium SA, Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIJA
Zoetis Lietuva UAB Tel: +370 5 2683634
Zoetis Lietuva UAB Tel: ++370 5 2683634
Zoetis LietuvaUAB Tel: +370 5 2683634
Zoetis Lietuva UAB Tel.: +370 5 2683634
Zoldipem
oziroma uspavala.
zoledroni c acid
zoledronska kislina
Zoledronic acid
Zoledronska
Zoledronic acid (%)
zoledronska kislina (%)
Zoledronic acid (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate.
Zoledronska kislina (5 mg v 100 ml raztopine, pripravljene za infuzijo) se aplicira prek infuzijskega sistema s prezračevanjem in sicer s stalno hitrostjo infundiranja.
Zoledronic acid (N = 1,065) event rate (%)
zoledronska kislina (N=1.065) delež dogodkov (%)
Zoledronic acid (N=1,065) event rate (%)
Zoledronska kislina (N=1.065) delež dogodkov (%)
zoledronic acid 4 mg
kislina 4 mg
zoledronic acid 4 mg
zoledronska kislina 4 mg
Zoledronic acid 4 mg
čas v študiji (tedni)
Zoledronic acid 4 mg (N=86)
zoledronska kislina 4 mg (N=86)
Zoledronic acid 4 mg (N=86)
zoledronske kisline 4 mg (N=86)
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Pri analizi večkratnih dogodkov se je pokazalo, da je zoledronska kislina 4 mg zmanjšala tveganje za SRE za 41 % (razmerje tveganj = 0,59, p = 0,019) v primerjavi s placebom.
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Pri analizi večkratnih dogodkov se je pokazalo, da je zoledronska kislina v odmerku 4 mg zmanjšala tveganje za SRE za 41 % (razmerje tveganj = 0,59, p=0,019) v primerjavi s placebom.
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Pri analizi večkratnih dogodkov se je pokazalo, da je zoledronska kislina zmanjšala tveganje za SRE za 41% (razmerje tveganj = 0,59, p=0,019) v primerjavi s placebom.
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
zmanjšanje tveganja za pojav večkratnih dogodkov** (%)
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronska kislina 4 mg je značilno (signifikantno) zmanjšala delež bolnikov, ki so doživeli vsaj po en z okostjem povezan dogodek (SRE), odložila mediano časa nastopa prvega z okostjem povezanega dogodka (SRE) za > 5 mesecev in zmanjšala letno incidenco dogodkov na bolnika – stopnjo obolevnosti skeleta.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronska kislina v odmerku 4 mg je značilno zmanjšala delež bolnikov, ki se jim je pojavil vsaj en z okostjem povezan dogodek (SRE), podaljšala je mediani čas do prvega SRE za > 5 mesecev in zmanjšala letno incidenco dogodkov na bolnika – stopnjo obolevnosti skeleta.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient – skeletal morbidity rate.
Zoledronska kislina 4 mg je značilno (signifikantno) zmanjšala delež bolnikov, ki so doživeli vsaj po en z okostjem povezan dogodek (SRE), odložila mediano časa nastopa prvega z okostjem povezanega dogodka (SRE) za > 5 mesecev in zmanjšala letno incidenco dogodkov na bolnika – stopnjo obolevnosti skeleta.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate.
Zoledronska kislina 4 mg je značilno (signifikantno) zmanjšala delež bolnikov, ki so doživeli vsaj po en z okostjem povezan dogodek (SRE), odložila mediano časa nastopa prvega z okostjem povezanega dogodka (SRE) za > 5 mesecev in zmanjšala letno incidenco dogodkov na bolnika – stopnjo obolevnosti skeleta.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronsko kislino 4 mg so proučevali tudi v dvojno slepi, randomizirani, s placebom nadzorovani študiji pri 228 bolnicah z dokazanimi kostnimi zasevki raka dojke, da bi ocenili učinek 4 mg zoledronske kisline na razmerje pogostnosti z okostjem povezanih dogodkov (SRE), izračunano iz celotnega števila SRE dogodkov (brez hiperkalciemije; prilagojenega na predhodne zlome), deljenega s celotnim obdobjem tveganja.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronsko kislino v odmerku 4 mg so proučevali tudi v dvojno slepem, randomiziranem, s placebom kontroliranem preskušanju pri 228 bolnicah z dokazanimi kostnimi metastazami raka dojke, da bi ocenili učinek 4 mg zoledronske kisline na pogostnost SRE, izračunano kot količnik celotnega števila SRE (brez hiperkalciemije in korigiranega na predhodne zlome) in celotnega obdobja tveganja.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of zoledronic acid 4 mg on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronsko kislino 4 mg so proučevali tudi v dvojno slepem, randomiziranem, s placebom kontroliranem preskušanju pri 228 bolnicah z dokazanimi kostnimi zasevki raka dojke, da bi ocenili učinek zoledronska kisline 4 mg na razmerje pogostnosti z okostjem povezanih dogodkov (SRE), izračunano iz celotnega števila SRE dogodkov (brez hiperkalciemije; prilagojenega na predhodne zlome), deljenega s celotnim obdobjem tveganja.
Zoledronic acid 8 mg (N=90)
Zoledronska kislina 8 mg (N=90)
Zoledronic acid 8 mg (N=90)
zoledronske kisline 8 mg (N=90)
Zoledronic Acid Accord
Zoledronska kislina Accord
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina Accord 4 mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronska kislina Accord 4 mg/5 ml koncentrat za raztopino za infundiranje zoledronska kislina
Zoledronic Acid Accord can also be used to treat the hypercalcaemia caused by tumours.
Zdravilo Zoledronic Acid Accord se lahko uporablja tudi za zdravljenje hiperkalciemije, ki jo povzročajo tumorji.
Zoledronic Acid Accord can only be obtained with a prescription and must only be prescribed and given by a healthcare professional who has experience in the use of this type of medicine given into a vein.
Zdravilo Zoledronic Acid Accord se izdaja samo na recept, predpiše ga pa lahko samo zdravnik, ki ima izkušnje z njegovim dajanjem v veno.
Zoledronic Acid Accord concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrata zdravila Zoledronska kislina Accord se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic Acid Accord contains sodium.
Zoledronska kislina Accord vsebuje natrij
Zoledronic Acid Accord is a medicine that contains the active substance zoledronic acid.
Zoledronic Acid Accord je zdravilo, ki vsebuje zdravilno učinkovino zoledronska kislina.
Zoledronic Acid Accord is a ‘generic medicine’.
Zdravilo Zoledronic Acid Accord je generično zdravilo.
Zoledronic Acid Accord is supplied as a liquid concentrate in a vial.
Zdravilo Zoledronska kislina Accord je v obliki tekočega koncentrata v viali.
Zoledronic Acid Accord must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zdravilo Zoledronska kislina Accord vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
Zoledronic Acid Accord must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zdravilo Zoledronska kislina Accord smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
Zoledronic acid Actavis
Zoledronska kislina Actavis
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is supplied as packs containing 1, 4 or 10 vials.
Zdravilo Zoledronska kislina Actavis 4 mg/5 ml koncentrat za raztopino za infundiranje je opremljeno v pakiranjih, ki vsebujejo 1, 4 ali 10 vial.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zdravilo Zoledronska kislina Actavis 4 mg/5 ml koncentrat za raztopino za infundiranje, dodatno razredčen v 100 ml (glejte poglavje 6.6), je treba dati v enkratni intravenski infuziji, ki traja najmanj 15 minut.
Zoledronic acid Actavis is a ‘generic medicine’.
Zdravilo Zoledronska kislina Actavis je „generično zdravilo“.
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zdravila Zoledronska kislina Actavis se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata, in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Zoledronic acid Actavis must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zdravilo Zoledronska kislina Actavis sme dati samo zdravstveni delavec, usposobljen za intravensko dajanje difosfonatov, tj. dajanje difosfonatov v veno.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronska kislina in vitro ne zavira humanih encimov s P450, ne kaže biotransformacije, v raziskavah na živalih pa so iz blata prestregli < 3% danega odmerka, kar kaže, da funkcija jeter nima pomembne vloge v farmakokinetiki zoledronske kisline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronska kislina in vitro ne zavira človeških encimov P450, ne kaže biotransformacije, v študijah na živalih pa se je v blatu pojavilo < 3% uporabljenega; to kaže, da delovanje jeter v farmakokinetiki zoledronske kisline nima pomembne vloge.
Zoledronic acid has been associated with reports of renal dysfunction.
Zoledronske kislino povezujejo s poročili o poslabšanju delovanja ledvic.
Zoledronic acid has been associated with reports of renal dysfunction.
Zoledronsko kislino povezujejo s poročili o poslabšanju delovanja ledvic.
Zoledronic Acid Hospira
Zoledronska kislina Hospira
Zoledronic Acid Hospira 4 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronska kislina Hospira 4 mg/100 ml (v okencu) raztopina za infundiranje zoledronska kislina
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zdravilo Zoledronska kislina Hospira 4 mg/100 ml raztopina za infundiranje vsebuje 4 mg zoledronske kisline v 100 ml raztopine za infundiranje za takojšnjo uporabo pri bolnikih z normalnim delovanjem ledvic.
Zoledronic Acid Hospira 4 mg/5 ml concentrate for solution for infusion
Zoledronska kislina Hospira 4mg/5 ml koncentrat za raztopino za infundiranje
Zoledronic Acid Hospira 4 mg/5 ml Sterile concentrate IV
Zoledronska kislina Hospira 4 mg/5 ml sterilni koncentrat i.v.
Zoledronic Acid Hospira 5 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronska kislina Hospira 5 mg/100 ml (na okencu) raztopina za infundiranje zoledronska kislina
Zoledronic Acid Hospira contains sodium
Zdravilo Zoledronska kislina Hospira vsebuje natrij
Zoledronic Acid Hospira contains the active substance zoledronic acid.
Zdravilo Zoledronska kislina Hospira vsebuje zdravilno učinkovino zoledronsko kislino.
Zoledronic Acid Hospira for infusion can be given to people aged 65 years and over.
Zdravilo Zoledronska kislina Hospira za infundiranje se lahko daje bolnikom, starim 65 let in več.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zdravilo Zoledronska kislina Hospira nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Zoledronic Acid Hospira is a clear and colourless solution.
Zdravilo Zoledronska kislina Hospira je bistra in brezbarvna raztopina.
Zoledronic Acid Hospira is a ‘generic’ and a ‘hybrid’ medicine.
Zdravilo Zoledronska kislina Hospira je „generično“ in „hibridno“ zdravilo.
Zoledronic Acid Hospira is not recommended for use in adolescents and children below the age of 18 years.
Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Zoledronska kislina Hospira ni priporočena.
Zoledronic Acid Hospira is ready for use.
Zdravilo Zoledronska kislina Hospira je pripravljeno za uporabo.
Zoledronic Acid Hospira is supplied as a liquid concentrate (referred to as a ‘concentrate for solution for infusion’ or ‘sterile concentrate’) in a vial.
Zdravilo Zoledronska kislina Hospira je tekoči koncentrat (imenovan "koncentrat za raztopino za infundiranje" ali "sterilni koncentrat") v viali.
Zoledronic Acid Hospira is supplied as packs containing one bag.
Zdravilo Zoledronska kislina Hospira je na voljo v pakiranjih, ki vsebujejo eno vrečo.
Zoledronic Acid Hospira may also cause other side effects
Zdravilo Zoledronska kislina Hospira lahko povzroča tudi druge neželene učinke
Zoledronic Acid Hospira may work for longer than one year, and your doctor will let you know if you need to be treated again.
Zdravilo Zoledronska kislina Hospira lahko učinkuje dlje kot eno leto, zato vam bo vaš zdravnik povedal, če vas je treba ponovno zdraviti.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as ‘IV’ administration).
Zdravilo Zoledronska kislina Hospira vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno, uprablja se tudi izraz ‘i.v.’ uporaba) dajanje difosfonatov.